#USA #Middleton #Imbed Biosciences #PainGuard #Microlyte

Imbed Biosciences Announces CMS Assignment of HCPCS Code A2040 for Microlyte® PainGuard™

Imbed Biosciences, based in Middleton, Wisconsin, has made headlines with a significant advancement in the healthcare landscape. The Centers for Medicare & Medicaid Services (CMS) have officially designated Healthcare Common Procedure Coding System (HCPCS) Level II code, A2040, specifically for Imbed's innovative product, Microlyte® PainGuard™. This synthetic wound matrix integrates silver for its antimicrobial properties with lidocaine HCl for efficient localized pain management.

Effective from April 1, 2026, this coding assignment empowers healthcare providers to accurately report and bill for Microlyte® PainGuard™ when submitting claims to insurance payers that recognize HCPCS Level II codes. Such an initiative greatly enhances billing clarity and supports efficient claims reporting while encouraging healthcare professionals to assess the appropriate application of this product within various clinical settings.

Terry Bromley, CEO of Imbed Biosciences, expressed the importance of the HCPCS code assignment, stating, "This designation helps provide clarity for providers as they incorporate the product into their clinical workflows." This beneficial move comes as part of Imbed's broader mission to support wound care through innovation.

Microlyte® PainGuard™ is designed to create a synthetic, antimicrobial, moist environment for healing, particularly in wound care scenarios. Offering non-opioid pain management abilities, the product builds upon the company’s advanced Synthetic Antimicrobial Matrix (SAM) Technology platform, catering to a diverse array of both acute and chronic wounds.

HCPCS Level II codes are instrumental in identifying medical products, supplies, and services that are not encapsulated by the Current Procedural Terminology (CPT) codes. By standardizing product identification on healthcare claims, the assignment of the A2040 code is expected to streamline administrative processes for healthcare providers and payers alike.

It is crucial to note, however, that receiving an HCPCS code does not guarantee coverage or payment, nor does it set a specific reimbursement level. Individual payers retain the autonomy to make coverage and payment decisions based on their policies, provider contracts, and specific patient scenarios.

Imbed Biosciences is dedicated to advancing the frontiers of wound care through its revolutionary Synthetic Antimicrobial Matrix Technology. This proprietary platform combines various therapeutic agents within an ultra-thin, biocompatible matrix, designed to foster skin regeneration in both chronic and acute wounds. The company’s expanding portfolio aims to mitigate infection risks, alleviate pain, and promote healing across the comprehensive spectrum of wound care.

As Imbed continues to innovate and expand, the recent code assignment for Microlyte® PainGuard™ marks a pivotal moment in the evolution of pain management and wound care solutions, strengthening Imbed’s position within the competitive landscape of medical devices.

For further information, visit Imbed Biosciences.